AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
B
Britannia Pharmaceuticals Ltd.Private
2 assets: 2 approvedApproved assets onlyNone on record————
Byondis B.V. logo
Byondis B.V.Private
1 asset: 1 Ph 1BYON4413Phase 1 · Acute Myeloid LeukemiaNone on record————
Cajal Therapeutics logo
Cajal TherapeuticsPrivate
1 asset: 1 Ph 1CTX001 (Cajal)Phase 1 · Chronic Kidney DiseaseNone on record————
Calico Life Sciences LLC logo
Calico Life Sciences LLCPrivate
2 assets: 1 Ph 3, 1 Ph 1FosigotifatorPhase 2/3Nov 2027Fosigotifator · Phase 1/2————
Calliditas Therapeutics logo
Calliditas TherapeuticsPrivate
1 asset: 1 approvedApproved assets onlyMar 2027Budesonide (targeted-release) · Approved—$75MJun 2024~16.9 qtrs$50M
C
cAMPfield TherapeuticsPrivate
1 asset: 1 Ph 3Prifemilast (HPP737)Phase 3 · PsoriasisPartial signalNone on record————
C
Cancer Research Technology LimitedPrivate
1 asset: 1 Ph 2RAD101Phase 2 · Brain MetastasesNone on record————
Candid Therapeutics logo
Candid TherapeuticsPrivate
3 assets: 3 Ph 1cizutamigPhase 1 · Systemic Lupus Erythematosus1 Jun 2027CND261 · Phase 1————
Capsida Biotherapeutics, Inc. logo
Capsida Biotherapeutics, Inc.Private
1 asset: 1 otherCAP-003Parkinson's DiseaseNone on record————
Cardior Pharmaceuticals GmbH logo
Cardior Pharmaceuticals GmbHPrivate
1 asset: 1 Ph 2CDR132LPhase 2 · Heart FailureWeak signal31 Dec 2026CDR132L · Phase 1————
Cardurion Pharmaceuticals logo
Cardurion PharmaceuticalsPrivate
1 asset: 1 Ph 2TovinontrinePhase 2 · Heart FailurePartial signalNone on record————
Carrick Therapeutics Limited logo
Carrick Therapeutics LimitedPrivate
1 asset: 1 Ph 2SamuraciclibPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signalNone on record————
CatalYm GmbH logo
CatalYm GmbHPrivate
1 asset: 1 Ph 2VisugromabPhase 2 · Non-Small Cell Lung CancerWeak signal30 Apr 2028Visugromab · Phase 1/2————
Celavie Biosciences, LLC logo
Celavie Biosciences, LLCPrivate
1 asset: 1 Ph 1OK99Phase 1 · Parkinson's DiseaseWeak signalNone on record————
C
Celest Therapeutics (Shanghai) Co., Ltd.Private
1 asset: 1 Ph 1SENTI-301APhase 1 · Hepatocellular CarcinomaNone on record————
Celgene Corporation logo
Celgene CorporationPrivate
3 assets: 2 approved, 1 Ph 2OnatasertibPhase 2 · Non-Small Cell Lung CancerWeak signalNone on record————
CellCentric Ltd. logo
CellCentric Ltd.Private
1 asset: 1 Ph 3InobrodibPhase 3 · Multiple Myeloma31 Mar 2027Inobrodib · Phase 1/2————
Cenna Biosciences logo
Cenna BiosciencesPrivate
1 asset: 1 Ph 18M2DPhase 1 · Alzheimer's DiseaseSep 20278M2D · Phase 1————
C
CephalonPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Cerecin (Singapore, formerly Accera, Nestle Health Science-backed) logo
Cerecin (Singapore, formerly Accera, Nestle Health Science-backed)Private
1 asset: 1 Ph 3TricaprilinPhase 3 · Alzheimer's DiseasePartial signalJan 2030Tricaprilin · Phase 3————
Cerevance logo
CerevancePrivate
1 asset: 1 Ph 3Solengepras (CVN424)Phase 3 · Parkinson's DiseaseWeak signalNone on record————
Changchun GeneScience Pharmaceutical logo
Changchun GeneScience PharmaceuticalPrivate
1 asset: 1 Ph 3Somatropin (Jintropin)Phase 3 · Chronic Kidney DiseasePartial signalNone on record————
Chendu DIAO Pharmaceutical Group logo
Chendu DIAO Pharmaceutical GroupPrivate
1 asset: 1 Ph 3DA-302168SPhase 3 · ObesityPartial signal12 Dec 2026DA-302168S · Phase 1————
C
Chengdu Diao Jiuhong PharmaceuticalPrivate
1 asset: 1 Ph 2ZhibitaiPhase 2 · Atherosclerotic Cardiovascular DiseaseNone on record————
Chengdu Easton Biopharmaceuticals logo
Chengdu Easton BiopharmaceuticalsPrivate
1 asset: 1 Ph 3YogliptinPhase 3 · Type 2 DiabetesPartial signalNone on record————
Chengdu Zenitar Biomedical Technology logo
Chengdu Zenitar Biomedical TechnologyPrivate
2 assets: 1 Ph 3, 1 Ph 2Purinostat MesylatePhase 3 · Diffuse Large B-Cell Lymphoma15 Dec 2026Purinostat Mesylate · Phase 1————
Cheplapharm Arzneimittel GmbH logo
Cheplapharm Arzneimittel GmbHPrivate
11 assets: 11 approvedApproved assets onlyNone on record————
C
Chia Tai Tianqing Pharmaceutical GroupPrivate
3 assets: 1 approved, 1 Ph 3, 1 Ph 2LanifibranorPhase 3 · MASH / NASHPartial signalNone on record————
Chiesi Farmaceutici logo
Chiesi FarmaceuticiPrivate
7 assets: 4 approved, 1 Ph 3, 2 Ph 2Beclomethasone dipropionate/formoterol fumaratePhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signalOct 2027pegunigalsidase alfa · Phase 2/3————
Chongqing Precision Biotech Co., Ltd logo
Chongqing Precision Biotech Co., LtdPrivate
3 assets: 2 Ph 2, 1 Ph 1CD123 targeted CAR-NK cellsPhase 1/2 · Acute Myeloid LeukemiaWeak signal31 Dec 2026BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech) · Phase 1/2————
C
Chuang Yi Global Asset Management Co., Ltd.Private
1 asset: 1 Ph 2LiafensinePhase 2 · Major Depressive DisorderReliable signalNone on record————
Cirius Therapeutics logo
Cirius TherapeuticsPrivate
1 asset: 1 Ph 2AzemiglitazonePhase 2 · Type 2 DiabetesNone on record————
CKD Bio Corporation logo
CKD Bio CorporationPrivate
1 asset: 1 otherL. lactis CKDB001Alzheimer's Disease31 May 2027L. lactis CKDB001 · Phase na————
Clasp Therapeutics, Inc. logo
Clasp Therapeutics, Inc.Private
1 asset: 1 Ph 1CLSP-5282Phase 1 · Non-Small Cell Lung CancerMay 2029CLSP-5282 · Phase 1————
Clexio Biosciences logo
Clexio BiosciencesPrivate
1 asset: 1 Ph 2Esketamine (CLE-100)Phase 2 · Major Depressive DisorderPartial signalNone on record————
Clinect logo
ClinectPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
CNX Therapeutics logo
CNX TherapeuticsPrivate
1 asset: 1 Ph 3NabiximolsPhase 3 · Multiple SclerosisPartial signalNone on record————
Concerto Biosciences logo
Concerto BiosciencesPrivate
1 asset: 1 Ph 1ENS-002Phase 1 · Atopic DermatitisWeak signalNone on record————
ConjuChem logo
ConjuChemPrivate
1 asset: 1 Ph 3AlbenatidePhase 3 · Type 2 DiabetesPartial signalNone on record————
Conjupro Biotherapeutics, Inc. logo
Conjupro Biotherapeutics, Inc.Private
1 asset: 1 Ph 3CPO301Phase 3 · Non-Small Cell Lung CancerMay 2027CPO301 · Phase 1————
ConSynance Therapeutics logo
ConSynance TherapeuticsPrivate
1 asset: 1 Ph 2CSTI-500Phase 2 · Prader-Willi SyndromeWeak signalJun 2027CSTI-500 · Phase 2————
Cordavis logo
CordavisPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
CoRegen, Inc. logo
CoRegen, Inc.Private
1 asset: 1 Ph 2CRG-150Phase 1/2 · HR+/HER2- Metastatic Breast CancerJun 2029CRG-150 · Phase 1/2————
CorrectSequence Therapeutics logo
CorrectSequence TherapeuticsPrivate
1 asset: 1 Ph 1CS-121Phase 1 · Familial Chylomicronemia SyndromeDec 2026CS-121 · Phase 1————
Corregene Biotechnology Co., Ltd logo
Corregene Biotechnology Co., LtdPrivate
1 asset: 1 Ph 1KRAS-specific Autologous TCR-T cellPhase 1 · Non-Small Cell Lung Cancer30 Nov 2028KRAS-specific Autologous TCR-T cell · Phase 1————
Corsera Health logo
Corsera HealthPrivate
1 asset: 1 Ph 1COR-1004Phase 1 · Atherosclerotic Cardiovascular DiseaseFeb 2027COR-1004 · Phase 1————
Corteria Pharmaceuticals logo
Corteria PharmaceuticalsPrivate
1 asset: 1 Ph 2Corteria COR-1167Phase 2 · Heart FailureJul 2027Corteria COR-1167 · Phase 2————
Corxel Pharmaceuticals logo
Corxel PharmaceuticalsPrivate
1 asset: 1 Ph 3Omecamtiv mecarbilPhase 3 · Heart FailureReliable signalSep 2027Omecamtiv mecarbil · Phase 3————
Cosette Pharmaceuticals logo
Cosette PharmaceuticalsPrivate
4 assets: 3 approved, 1 Ph 2bremelanotidePhase 2 · ObesityReliable signalNone on record————
CREATE Medicines logo
CREATE MedicinesPrivate
2 assets: 2 Ph 1MT-302Phase 1 · Non-Small Cell Lung Cancer31 Jan 2027MT-304 · Phase 1————
Crossbow Therapeutics, Inc. logo
Crossbow Therapeutics, Inc.Private
1 asset: 1 Ph 1CBX-250Phase 1 · Acute Myeloid LeukemiaJan 2027CBX-250 · Phase 1————
CSL Behring logo
CSL BehringPrivate
1 asset: 1 approvedApproved assets only4 Oct 2028etranacogene dezaparvovec · Phase 3————
CSL Seqirus logo
CSL SeqirusPrivate
2 assets: 2 approvedApproved assets onlyApr 2027Epinephrine · Approved————
C
CSPC Megalith BiopharmaceuticalPrivate
1 asset: 1 Ph 3Sutantatug envedotinPhase 3 · Cervical Cancer16 Jan 2027Sutantatug envedotin · Phase 1/2————
CSPC Ouyi Pharmaceutical Co. logo
CSPC Ouyi Pharmaceutical Co.Private
1 asset: 1 Ph 3SYHX1901Phase 3 · PsoriasisPartial signal28 Apr 2027SYHX1901 · Phase 3————
C
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Private
4 assets: 4 Ph 3stapokibartPhase 3 · Atopic DermatitisReliable signal25 Dec 2026Docetaxel (HB1801) · Phase 2————
Cullgen (Shanghai),Inc logo
Cullgen (Shanghai),IncPrivate
1 asset: 1 Ph 1CG009301Phase 1 · Acute Myeloid Leukemia30 Dec 2027CG009301 · Phase 1————
Cyclarity Therapeutics logo
Cyclarity TherapeuticsPrivate
1 asset: 1 Ph 1UDP-003Phase 1 · Atherosclerotic Cardiovascular Disease30 Dec 2026UDP-003 · Phase 1————
Cycle Pharmaceuticals Ltd. logo
Cycle Pharmaceuticals Ltd.Private
2 assets: 2 approvedApproved assets onlyNone on record————
Cyto Therapeutics Pty Limited logo
Cyto Therapeutics Pty LimitedPrivate
1 asset: 1 Ph 1ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signalNone on record————
C
Cytocraft Biopharmaceutical Co., Ltd.Private
1 asset: 1 Ph 1SDT-M001Phase 1 · Non-Small Cell Lung Cancer26 Jun 2027SDT-M001 · Phase 1————
CytosinLab Therapeutics Co., Ltd. logo
CytosinLab Therapeutics Co., Ltd.Private
1 asset: 1 Ph 2CTS2190Phase 1/2 · Non-Small Cell Lung CancerNone on record————
DalCor Pharmaceuticals logo
DalCor PharmaceuticalsPrivate
1 asset: 1 Ph 3DalcetrapibPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signalAug 2027Dalcetrapib · Phase 3————
D
Day One Biopharmaceuticals, Inc.Private
1 asset: 1 approvedApproved assets only31 May 2027Tovorafenib · Phase 2————
Debiopharm logo
DebiopharmPrivate
1 asset: 1 Ph 2Debio 1562MPhase 1/2 · Acute Myeloid LeukemiaNone on record————
Debiopharm International SA logo
Debiopharm International SAPrivate
1 asset: 1 Ph 2ZedoresertibPhase 1/2 · HR+/HER2- Metastatic Breast CancerDec 2027Zedoresertib · Phase 1————
DEKA Biosciences logo
DEKA BiosciencesPrivate
1 asset: 1 Ph 1DK210Phase 1 · Non-Small Cell Lung CancerNone on record————
Denovo Biopharma logo
Denovo BiopharmaPrivate
1 asset: 1 Ph 2LiafensinePhase 2 · Major Depressive DisorderReliable signalNone on record————
Dermavon Holdings logo
Dermavon HoldingsPrivate
1 asset: 1 Ph 3CMS-D001Phase 2/3 · Psoriasis31 Jan 2027CMS-D001 · Phase 2————
Desitin Arzneimittel GmbH logo
Desitin Arzneimittel GmbHPrivate
1 asset: 1 Ph 3Piribedil (Clarium)Phase 3 · Parkinson's DiseasePartial signalNone on record————
DeuterOncology logo
DeuterOncologyPrivate
1 asset: 1 Ph 1DO-2Phase 1 · Non-Small Cell Lung CancerSep 2027DO-2 · Phase 1————
D
Dicerna Pharmaceuticals, Inc.Private
1 asset: 1 Ph 3LepodisiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signalMar 2027Lepodisiran · Phase 1————
Direct Biologics logo
Direct BiologicsPrivate
1 asset: 1 Ph 2ExoFloPhase 2 · Crohn's DiseaseWeak signalJun 2027ExoFlo · Phase 2————
Dongguan HEC Biopharmaceutical logo
Dongguan HEC BiopharmaceuticalPrivate
1 asset: 1 Ph 2HEC88473Phase 2 · Type 2 DiabetesWeak signalNone on record————
Dracen Pharmaceuticals logo
Dracen PharmaceuticalsPrivate
1 asset: 1 Ph 2SirpiglenastatPhase 2 · Non-Small Cell Lung CancerWeak signalNone on record————
Draig Therapeutics logo
Draig TherapeuticsPrivate
1 asset: 1 Ph 2DT-101Phase 2 · Major Depressive DisorderMay 2027DT-101 · Phase 2————
Dren Bio logo
Dren BioPrivate
1 asset: 1 Ph 1DR-0202Phase 1 · Non-Small Cell Lung CancerJul 2027DR-0202 · Phase 1————
E
EA PharmaPrivate
1 asset: 1 Ph 3UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal22 Feb 2032Upacicalcet · Phase 3————
E
EccogenePrivate
2 assets: 1 Ph 3, 1 Ph 2elecoglipronPhase 3 · ObesityReliable signalDec 2026ECC4703 · Phase 1————
Eddingpharm (Zhuhai) Co., Ltd. logo
Eddingpharm (Zhuhai) Co., Ltd.Private
1 asset: 1 Ph 2EDP167Phase 2 · Atherosclerotic Cardiovascular DiseaseWeak signalNov 2027EDP167 · Phase 2————
Edgewood Oncology Inc. logo
Edgewood Oncology Inc.Private
1 asset: 1 Ph 1BTX-A51Phase 1 · Acute Myeloid LeukemiaNone on record————
EHL Bio logo
EHL BioPrivate
1 asset: 1 Ph 3ADSTEMPhase 3 · Atopic DermatitisSep 2029ADSTEM · Phase 3————
EicOsis Human Health, Inc. logo
EicOsis Human Health, Inc.Private
1 asset: 1 Ph 2EC5026Phase 1/2 · Parkinson's DiseaseDec 2026EC5026 · Phase 1/2————
E
Elevar Therapeutics, Inc.Private
3 assets: 1 approved, 2 Ph 3ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signalJul 2027Apatinib · Phase 2————
E
Elion Oncology, Inc.Private
1 asset: 1 Ph 2EniluracilPhase 2 · Metastatic Colorectal CancerNone on record————
Elixiron Immunotherapeutics logo
Elixiron ImmunotherapeuticsPrivate
1 asset: 1 Ph 2EnrupatinibPhase 2 · Alzheimer's DiseaseAug 2027Enrupatinib · Phase 1————
Ellipses Pharma logo
Ellipses PharmaPrivate
3 assets: 3 Ph 2LunbotinibPhase 1/2 · Non-Small Cell Lung Cancer31 Dec 2026Lunbotinib · Phase 1/2————
Elpiscience (Suzhou) Biopharma, Ltd. logo
Elpiscience (Suzhou) Biopharma, Ltd.Private
1 asset: 1 Ph 3OrdastobartPhase 2/3 · Head and Neck Squamous Cell Carcinoma28 Feb 2027Ordastobart · Phase 2————
EMD Serono logo
EMD SeronoPrivate
2 assets: 2 approvedApproved assets onlyNone on record————
Empros Pharma logo
Empros PharmaPrivate
1 asset: 1 Ph 2Orlistat/acarbose (EMP16)Phase 2 · ObesityReliable signalNone on record————
Encoded Therapeutics, Inc. logo
Encoded Therapeutics, Inc.Private
1 asset: 1 Ph 2ETX101Phase 1/2 · EpilepsyJun 2028ETX101 · Phase 1/2————
E
Encore DermatologyPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
EncuraGen logo
EncuraGenPrivate
1 asset: 1 other(PEG)-BHD1028ObesityNone on record————
Engrail Therapeutics logo
Engrail TherapeuticsPrivate
1 asset: 1 Ph 1ENX-104Phase 1 · Major Depressive DisorderWeak signalNone on record————
Enterin Inc. logo
Enterin Inc.Private
1 asset: 1 Ph 2ENT-01Phase 2 · Parkinson's DiseasePartial signalNone on record————
Enveda Therapeutics logo
Enveda TherapeuticsPrivate
1 asset: 1 Ph 2ENV-294Phase 2 · Atopic DermatitisWeak signalDec 2026ENV-294 · Phase 2————
Enyo Pharma logo
Enyo PharmaPrivate
1 asset: 1 Ph 2VonafexorPhase 2 · Chronic Kidney DiseasePartial signalNone on record————
EpiBiologics logo
EpiBiologicsPrivate
1 asset: 1 Ph 1EPI-326Phase 1 · Non-Small Cell Lung CancerJul 2029EPI-326 · Phase 1————
E
EpiDestinyPrivate
1 asset: 1 Ph 2Decitabine/Tetrahydrouridine (NDec)Phase 2 · Sickle Cell DiseaseNone on record————
EpiEndo Pharmaceuticals logo
EpiEndo PharmaceuticalsPrivate
1 asset: 1 Ph 2glasmacinalPhase 2 · Chronic Obstructive Pulmonary DiseasePartial signalNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415